Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 7811-7820 Newer>

The Motley Fool August 18, 2011 Brian Orelli	A Poke in the Eye From the FDA FDA extends its review of Regeneron Pharmaceuticals' macular degeneration drug by three months.
The Motley Fool August 17, 2011 Brian Orelli	Generic-Drug Makers Pay for Speed Lower margins -- faster.
The Motley Fool August 17, 2011 Ilan Moscovitz	Pfizer Is Cheaper Than You Think Let's examine Pfizer alongside some of its peers for additional context.
The Motley Fool August 17, 2011 Alexander Crawford	Biotech Analysts See Buying Opportunities From Sell-Off We compiled a list of biotech companies that have underperformed the S&P 500 over the last month but maintain a solid list of fundamentals.
The Motley Fool August 16, 2011 Jeremy Phillips	Read This Before You Think About Selling Sequenom I consider a debt-to-equity ratio below 50% to be healthy, though the number varies by industry. Sequenom is currently below this level, at 1.1%.
The Motley Fool August 16, 2011 Anders Bylund	Boring Business, Exciting Results Measurement tools make for boring cocktail-party discussion, but there's an exciting investment opportunity brewing in this industry. Agilent's business now rests on a balanced set of growing legs.
The Motley Fool August 16, 2011 Brian Orelli	Keeping Those Little Blue Pill Sales Up Pfizer wins a patent lawsuit for Viagra.
The Motley Fool August 15, 2011 Jim Royal	6 Wild Bets on Biotech Riches The most interesting biotech tickers.
The Motley Fool August 15, 2011 Brian Orelli	Another Partner, but Still No Data Sequenom signs up a European partner.
The Motley Fool August 14, 2011 Rex Moore	Warning: Vertex Pharmaceuticals May Be Hiding Weakness Here are Vertex Pharmaceuticals' numbers, as well as a bonus look at a few other companies in its industry.
<Older 7811-7820 Newer> Return to current articles.